| Year |
Citation |
Score |
| 2024 |
Nishiguchi G, Mascibroda LG, Young SM, Caine EA, Abdelhamed S, Kooijman JJ, Miller DJ, Das S, McGowan K, Mayasundari A, Shi Z, Barajas JM, Hiltenbrand R, Aggarwal A, Chang Y, ... ... Shelat AA, et al. Selective CK1α degraders exert antiproliferative activity against a broad range of human cancer cell lines. Nature Communications. 15: 482. PMID 38228616 DOI: 10.1038/s41467-024-44698-1 |
0.34 |
|
| 2022 |
Roussel MF, Jonchere B, Williams J, Zindy F, Liu J, Robinson S, Farmer DM, Min J, Yang L, Stripay JL, Wang Y, Freeman BB, Yu J, Shelat AA, Rankovic Z. Combination of ribociclib with BET-bromodomain and PI3K/mTOR inhibitors for medulloblastoma treatment in vitro and in vivo. Molecular Cancer Therapeutics. PMID 36318650 DOI: 10.1158/1535-7163.MCT-21-0896 |
0.373 |
|
| 2021 |
Rankovic Z, Min J, Mayasundari A, Keramatnia F, Jonchere B, Yang SW, Jarusiewicz JA, Actis M, Das S, Young BM, Slavish PJ, Yang L, Li Y, Fu X, Garrett SH, ... ... Shelat AA, et al. Phenyl-Glutarimides: Alternative Cereblon Binders for the Design of PROTACs. Angewandte Chemie (International Ed. in English). PMID 34614283 DOI: 10.1002/anie.202108848 |
0.771 |
|
| 2021 |
Nishiguchi G, Das S, Ochoada J, Long H, Lee RE, Rankovic Z, Shelat AA. Evaluating and evolving a screening library in academia: the St Jude approach. Drug Discovery Today. PMID 33453364 DOI: 10.1016/j.drudis.2021.01.005 |
0.317 |
|
| 2020 |
Slavish PJ, Chi L, Yun MK, Tsurkan L, Martinez NE, Jonchere B, Chai SC, Connelly M, Waddell MB, Das S, Neale G, Li Z, Shadrick WR, Olsen RR, Freeman KW, ... ... Shelat AA, et al. Bromodomain-selective BET inhibitors are potent antitumor agents against MYC-driven pediatric cancer. Cancer Research. PMID 32651255 DOI: 10.1158/0008-5472.Can-19-3934 |
0.606 |
|
| 2020 |
Twarog NR, Connelly M, Shelat AA. A critical evaluation of methods to interpret drug combinations. Scientific Reports. 10: 5144. PMID 32198459 DOI: 10.1038/S41598-020-61923-1 |
0.356 |
|
| 2020 |
Gose T, Shafi T, Fukuda Y, Das S, Wang Y, Allcock A, Gavan McHarg A, Lynch J, Chen T, Tamai I, Shelat A, Ford RC, Schuetz JD. ABCG2 requires a single aromatic amino acid to "clamp" substrates and inhibitors into the binding pocket. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. PMID 32067270 DOI: 10.1096/Fj.201902338Rr |
0.312 |
|
| 2020 |
Benzel J, Sauter M, Mack N, Davis A, Weiss J, Uhl P, Burhenne J, Maass KK, Hübner J, Witt H, Shelat A, Gajjar A, Upadhyaya SA, Camgoz A, Buchholz F, et al. Abstract A25: Evaluation of Drug Disposition in Supratentorial Ependymoma Cancer Research. 80. DOI: 10.1158/1538-7445.Pedca19-A25 |
0.444 |
|
| 2019 |
Genthe JR, Min J, Farmer DM, Shelat AA, Grenet JA, Lin W, Finkelstein D, Vrijens K, Chen T, Guy RK, Clements WK, Roussel MF. Ventromorphins: A New Class of Small Molecule Activators of the Canonical BMP Signaling Pathway. Acs Chemical Biology. PMID 31251562 DOI: 10.1021/acschembio.9b00488 |
0.432 |
|
| 2019 |
Drenberg CD, Shelat A, Dang J, Cotton A, Orwick SJ, Li M, Jeon JY, Fu Q, Buelow DR, Pioso M, Hu S, Inaba H, Ribeiro RC, Rubnitz JE, Gruber TA, et al. A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML. Nature Communications. 10: 2189. PMID 31097698 DOI: 10.1038/S41467-019-09917-0 |
0.565 |
|
| 2019 |
Jonchere B, Stripay J, Pribnow A, Zindy F, Min J, Freeman B, Shelat A, Rankovic Z, Roussel M. PDTM-02. TARGETING THE RB PATHWAY IN MEDULLOBLASTOMA Neuro-Oncology. 21: vi187-vi187. DOI: 10.1093/Neuonc/Noz175.778 |
0.508 |
|
| 2018 |
Ling T, Maier J, Das S, Budhraja A, Bassett R, Potts MB, Shelat A, Rankovic Z, Opferman JT, Rivas F. Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents. European Journal of Medicinal Chemistry. 164: 391-398. PMID 30611980 DOI: 10.1016/J.Ejmech.2018.12.059 |
0.443 |
|
| 2018 |
Loh A, Bradley C, Karlstrom A, Krafcik F, Dyer MA, Stewart E, Goshorn R, Chen X, Daryani V, Stewart C, Calabrese C, Funk A, Miller G, Shelat A, Bahrami A. Combinatorial Screening Using Orthotopic Patient Derived Xenograft-Expanded Early Phase Cultures of Osteosarcoma Identify Novel Therapeutic Drug Combinations. Cancer Letters. PMID 30395907 DOI: 10.1016/J.Canlet.2018.10.033 |
0.487 |
|
| 2018 |
Stewart E, McEvoy J, Wang H, Chen X, Honnell V, Ocarz M, Gordon B, Dapper J, Blankenship K, Yang Y, Li Y, Shaw TI, Cho JH, Wang X, Xu B, ... ... Shelat A, et al. Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses. Cancer Cell. PMID 30146332 DOI: 10.1016/J.Ccell.2018.07.012 |
0.327 |
|
| 2018 |
Bharatham N, Slavish PJ, Young BM, Shelat AA. The role of ZA channel water-mediated interactions in the design of bromodomain-selective BET inhibitors. Journal of Molecular Graphics & Modelling. 81: 197-210. PMID 29605436 DOI: 10.1016/J.Jmgm.2018.03.005 |
0.313 |
|
| 2018 |
Ling T, Lang W, Feng X, Das S, Maier J, Jeffries C, Shelat A, Rivas F. Novel vitexin-inspired scaffold against leukemia. European Journal of Medicinal Chemistry. 146: 501-510. PMID 29407975 DOI: 10.1016/J.Ejmech.2018.01.004 |
0.429 |
|
| 2018 |
Nimmervoll B, Boulos N, Bianski BM, Dapper J, DeCuypere M, Shelat AA, Terranova S, Terhune HE, Gajjar A, Patel YT, Freeman BB, Onar-Thomas A, Stewart CF, Roussel MF, Guy RK, et al. Establishing A Preclinical Multidisciplinary Board for Brain Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29301833 DOI: 10.1158/1078-0432.Ccr-17-2168 |
0.771 |
|
| 2018 |
Iacobucci I, Varotto E, Qu C, Janke L, Seth A, Shelat A, Freeman B, Kennedy J, Sperling AS, Lindsley RC, Dickerson K, Payne-Turner D, Morris SM, Ghosn N, Ebert BL, et al. Multiplex CRISPR/Cas9-Based Genome Editing of Mouse Hematopoietic Stem Cells Recapitulates Acute Erythroid Leukemia and Identifies Therapeutic Targets Blood. 132: 5-5. DOI: 10.1182/Blood-2018-99-118817 |
0.341 |
|
| 2018 |
Shelat AA, Tinkle CL, Stewart E, Federico SM, Bianski B, Mellado-Lagarde M. Abstract B36: A biomarker-guided approach to combining PARP inhibitors with radiotherapy in pediatric sarcomas Clinical Cancer Research. 24. DOI: 10.1158/1557-3265.Sarcomas17-B36 |
0.369 |
|
| 2018 |
Miller AL, Slavish PJ, Young BM, Potter PM, Shelat AA, Yoon KJ. Abstract 5794: Targeting the BD2 BET bromodomain to inhibit proliferation of pancreatic ductal adenocarcinoma cells Cancer Research. 78: 5794-5794. DOI: 10.1158/1538-7445.Am2018-5794 |
0.368 |
|
| 2017 |
Ortiz D, Guiguemde WA, Hammill JT, Carrillo AK, Chen Y, Connelly M, Stalheim K, Elya C, Johnson A, Min J, Shelat A, Smithson DC, Yang L, Zhu F, Guy RK, et al. Discovery of novel, orally bioavailable, antileishmanial compounds using phenotypic screening. Plos Neglected Tropical Diseases. 11: e0006157. PMID 29287089 DOI: 10.1371/Journal.Pntd.0006157 |
0.793 |
|
| 2017 |
Shadrick WR, Slavish PJ, Chai SC, Waddell B, Connelly M, Low JA, Tallant C, Young BM, Bharatham N, Knapp S, Boyd VA, Morfouace M, Roussel MF, Chen T, Lee RE, ... ... Shelat AA, et al. Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors. Bioorganic & Medicinal Chemistry. PMID 29170024 DOI: 10.1016/J.Bmc.2017.10.042 |
0.319 |
|
| 2017 |
Riniker S, Landrum GA, Montanari F, Villalba SD, Maier J, Jansen JM, Walters WP, Shelat AA. Virtual-screening workflow tutorials and prospective results from the Teach-Discover-Treat competition 2014 against malaria. F1000research. 6: 1136. PMID 28928948 DOI: 10.12688/F1000Research.11905.2 |
0.427 |
|
| 2017 |
Genthe JR, Min J, Farmer DM, Shelat AA, Grenet JA, Lin W, Finkelstein DB, Vrijens K, Chen T, Guy RK, Clements WK, Roussel MF. Ventromorphins: A new class of small molecule activators of the canonical BMP signaling pathway. Acs Chemical Biology. PMID 28787124 DOI: 10.1021/Acschembio.7B00527 |
0.566 |
|
| 2017 |
Yang J, Milasta S, Hu D, AlTahan A, Interiano R, Zhou J, Davidson J, Low J, Lin W, Bao J, Goh P, Nathwani A, Wang R, Wang Y, Ong SS, ... ... Shelat AA, et al. Targeting histone demethylases in MYC-driven neuroblastomas with ciclopirox. Cancer Research. PMID 28684529 DOI: 10.1158/0008-5472.Can-16-0826 |
0.54 |
|
| 2017 |
Scott DC, Hammill JT, Min J, Rhee DY, Connelly M, Sviderskiy VO, Bhasin D, Chen Y, Ong SS, Chai SC, Goktug AN, Huang G, Monda JK, Low J, Kim HS, ... ... Shelat AA, et al. Blocking an N-terminal acetylation-dependent protein interaction inhibits an E3 ligase. Nature Chemical Biology. PMID 28581483 DOI: 10.1038/Nchembio.2386 |
0.75 |
|
| 2017 |
Verras A, Waller CL, Gedeck P, Green D, Kogej T, Raichurkar AV, Panda M, Shelat AA, Clark JA, Guy RK, Papadatos G, Burrows JN. Shared Consensus Machine Learning Models for Predicting Blood Stage Malaria Inhibition. Journal of Chemical Information and Modeling. PMID 28257198 DOI: 10.1021/Acs.Jcim.6B00572 |
0.587 |
|
| 2017 |
Mellado-Lagarde M, Federico SM, Tinkle C, Shelat A, Stewart E. PARP inhibitor combination therapy in desmoplastic small round cell tumors. Journal of Clinical Oncology. 35: e23212-e23212. DOI: 10.1200/Jco.2017.35.15_Suppl.E23212 |
0.366 |
|
| 2017 |
Shelat A, Tinkle C, Stewart E, Federico SM, Bianski B, Mellado-Lagarde M. A biomarker-guided approach to combining PARP inhibitors with radiotherapy in pediatric solid tumors. Journal of Clinical Oncology. 35: 10556-10556. DOI: 10.1200/Jco.2017.35.15_Suppl.10556 |
0.35 |
|
| 2017 |
Stewart E, Honnell V, Ocarz M, Blankenship K, Dapper J, Freeman B, Shelat A, Pappo AS, Dyer MA. Targeting the cell cycle for cancer therapy in rhabdomyosarcoma. Journal of Clinical Oncology. 35: 10535-10535. DOI: 10.1200/Jco.2017.35.15_Suppl.10535 |
0.32 |
|
| 2016 |
Zhang J, Bowling JJ, Smithson D, Clark J, Jacob MR, Khan SI, Tekwani BL, Connelly M, Samoylenko V, Ibrahim MA, Zaki MA, Wang M, Hester JP, Tu Y, Jeffries C, ... ... Shelat AA, et al. Diversity-oriented natural product platform identifies plant constituents targeting Plasmodium falciparum. Malaria Journal. 15: 270. PMID 27165106 DOI: 10.1186/S12936-016-1313-7 |
0.796 |
|
| 2016 |
Drenberg CD, Buaboonnam J, Orwick SJ, Hu S, Li L, Fan Y, Shelat AA, Guy RK, Rubnitz J, Baker SD. Evaluation of artemisinins for the treatment of acute myeloid leukemia. Cancer Chemotherapy and Pharmacology. PMID 27125973 DOI: 10.1007/S00280-016-3038-2 |
0.476 |
|
| 2016 |
Twarog NR, Low JA, Currier DG, Miller G, Chen T, Shelat AA. Robust Classification of Small-Molecule Mechanism of Action Using a Minimalist High-Content Microscopy Screen and Multidimensional Phenotypic Trajectory Analysis. Plos One. 11: e0149439. PMID 26886014 DOI: 10.1371/Journal.Pone.0149439 |
0.414 |
|
| 2016 |
Kovar H, Amatruda J, Brunet E, Burdach S, Cidre-Aranaz F, de Alava E, Dirksen U, van der Ent W, Grohar P, Grünewald TG, Helman L, Houghton P, Iljin K, Korsching E, Ladanyi M, ... ... Shelat A, et al. The second European interdisciplinary Ewing sarcoma research summit - A joint effort to deconstructing the multiple layers of a complex disease. Oncotarget. PMID 26802024 DOI: 10.18632/Oncotarget.6937 |
0.354 |
|
| 2016 |
Stewart E, Bradley C, Shelat A, Pappo A, Dyer MA. Abstract A09: Preclinical trial using the combination of panobinostat with bortezomib in human orthotopic xenograft mouse models of rhabdomyosarcoma Cancer Research. 76. DOI: 10.1158/1538-7445.Pedca15-A09 |
0.369 |
|
| 2016 |
Min J, Scott DC, Chai SC, Goktug AN, Hammill JT, Huang G, Connelly MC, Matheny A, Shelat A, Singh B, Chen T, Schulman BA, Guy RK. Abstract LB-056: Discovery of novel small molecule inhibitors of the DCN1-Ubc12 interaction by high throughput screening technology Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-056 |
0.769 |
|
| 2016 |
Drenberg CD, Shelat A, Orwick SJ, Inaba H, Ribeiro RC, Rubnitz JE, Gruber TA, Guy RK, Baker SD. Abstract 4786: Integrated high-throughput screen to identify treatment leads for pediatric AML Cancer Research. 76: 4786-4786. DOI: 10.1158/1538-7445.Am2016-4786 |
0.464 |
|
| 2016 |
Nimmervoll B, Patel Y, Bianski B, DeCuypere M, Shelat A, Stewart C, Merchant T, Guy RK, Gilbertson R. PCM-22A NEW APPROACH OF PRECLINICAL TESTING OF CHEMOTHERAPIES - AN EXAMPLE OF BRAIN TUMOUR THERAPY Neuro-Oncology. 18: iii144-iii144. DOI: 10.1093/Neuonc/Now080.22 |
0.47 |
|
| 2015 |
Morfouace M, Nimmervoll B, Boulos N, Patel YT, Shelat A, Freeman BB, Robinson GW, Wright K, Gajjar A, Stewart CF, Gilbertson RJ, Roussel MF. Preclinical studies of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in pediatric brain tumors. Journal of Neuro-Oncology. PMID 26518542 DOI: 10.1007/S11060-015-1965-0 |
0.776 |
|
| 2015 |
Iconaru LI, Ban D, Bharatham K, Ramanathan A, Zhang W, Shelat AA, Zuo J, Kriwacki RW. Discovery of Small Molecules that Inhibit the Disordered Protein, p27(Kip1). Scientific Reports. 5: 15686. PMID 26507530 DOI: 10.1038/Srep15686 |
0.358 |
|
| 2015 |
Morfouace M, Cheepala S, Jackson S, Fukuda Y, Patel YT, Fatima S, Kawauchi D, Shelat AA, Stewart CF, Sorrentino BP, Schuetz JD, Roussel MF. ABCG2 Transporter Expression Impacts Group 3 Medulloblastoma Response to Chemotherapy. Cancer Research. PMID 26199091 DOI: 10.1158/0008-5472.Can-15-0030 |
0.348 |
|
| 2015 |
Stewart E, Federico S, Karlstrom A, Shelat A, Sablauer A, Pappo A, Dyer MA. The Childhood Solid Tumor Network: A new resource for the developmental biology and oncology research communities. Developmental Biology. PMID 26068307 DOI: 10.1016/J.Ydbio.2015.03.001 |
0.311 |
|
| 2015 |
Stewart E, Federico S, Karlstrom A, Shelat A, Sablauer A, Pappo A, Dyer MA. The childhood solid tumor network: A new resource for the developmental biology and oncology research communities. Developmental Biology. PMID 25863122 DOI: 10.1016/J.Ydbio.2015.02.002 |
0.372 |
|
| 2015 |
Gupte A, Baker EK, Wan SS, Stewart E, Loh A, Shelat AA, Gould CM, Chalk AM, Taylor S, Lackovic K, Karlström Å, Mutsaers AJ, Desai J, Madhamshettiwar PB, Zannettino AC, et al. Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 3216-29. PMID 25862761 DOI: 10.1158/1078-0432.Ccr-14-3026 |
0.373 |
|
| 2015 |
Sharma LK, Leonardi R, Lin W, Boyd VA, Goktug A, Shelat AA, Chen T, Jackowski S, Rock CO. A high-throughput screen reveals new small-molecule activators and inhibitors of pantothenate kinases. Journal of Medicinal Chemistry. 58: 1563-8. PMID 25569308 DOI: 10.1021/Jm501585Q |
0.467 |
|
| 2015 |
Morfouace M, Patel Y, Shelat A, Kawauchi D, Robinson GW, Guy K, Gilbertson RJ, Stewart C, Gajjar A, Roussel MF. Abstract IA21: Pediatric medulloblastoma: Drug screens and preclinical studies Brain. 75. DOI: 10.1158/1538-7445.Brain15-Ia21 |
0.431 |
|
| 2014 |
Jiménez-Díaz MB, Ebert D, Salinas Y, Pradhan A, Lehane AM, Myrand-Lapierre ME, O'Loughlin KG, Shackleford DM, Justino de Almeida M, Carrillo AK, Clark JA, Dennis AS, Diep J, Deng X, Duffy S, ... ... Shelat A, et al. (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium. Proceedings of the National Academy of Sciences of the United States of America. 111: E5455-62. PMID 25453091 DOI: 10.1073/Pnas.1414221111 |
0.58 |
|
| 2014 |
Stewart E, Goshorn R, Bradley C, Griffiths LM, Benavente C, Twarog NR, Miller GM, Caufield W, Freeman BB, Bahrami A, Pappo A, Wu J, Loh A, Karlström Å, Calabrese C, ... ... Shelat AA, et al. Targeting the DNA repair pathway in Ewing sarcoma. Cell Reports. 9: 829-41. PMID 25437539 DOI: 10.1016/J.Celrep.2014.09.028 |
0.302 |
|
| 2014 |
Morfouace M, Shelat A, Jacus M, Freeman BB, Turner D, Robinson S, Zindy F, Wang YD, Finkelstein D, Ayrault O, Bihannic L, Puget S, Li XN, Olson JM, Robinson GW, et al. Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma. Cancer Cell. 25: 516-29. PMID 24684846 DOI: 10.1016/J.Ccr.2014.02.009 |
0.57 |
|
| 2014 |
Yang J, Liang Q, Wang M, Jeffries C, Smithson D, Tu Y, Boulos N, Jacob MR, Shelat AA, Wu Y, Ravu RR, Gilbertson R, Avery MA, Khan IA, Walker LA, et al. UPLC-MS-ELSD-PDA as a powerful dereplication tool to facilitate compound identification from small-molecule natural product libraries. Journal of Natural Products. 77: 902-9. PMID 24617915 DOI: 10.1021/Np4009706 |
0.788 |
|
| 2014 |
Guo K, Shelat AA, Guy RK, Kastan MB. Development of a cell-based, high-throughput screening assay for ATM kinase inhibitors. Journal of Biomolecular Screening. 19: 538-46. PMID 24464432 DOI: 10.1177/1087057113520325 |
0.575 |
|
| 2014 |
Bharatham N, Bharatham K, Shelat AA, Bashford D. Ligand binding mode prediction by docking: mdm2/mdmx inhibitors as a case study. Journal of Chemical Information and Modeling. 54: 648-59. PMID 24358984 DOI: 10.1021/Ci4004656 |
0.386 |
|
| 2014 |
Gottardo NG, Hansford JR, McGlade JP, Alvaro F, Ashley DM, Bailey S, Baker DL, Bourdeaut F, Cho YJ, Clay M, Clifford SC, Cohn RJ, Cole CH, Dallas PB, Downie P, ... ... Shelat AA, et al. Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathologica. 127: 189-201. PMID 24264598 DOI: 10.1007/S00401-013-1213-7 |
0.368 |
|
| 2014 |
Singh H, Shelat AA, Singh A, Boulos N, Williams RT, Guy RK. A screening-based approach to circumvent tumor microenvironment-driven intrinsic resistance to BCR-ABL+ inhibitors in Ph+ acute lymphoblastic leukemia. Journal of Biomolecular Screening. 19: 158-67. PMID 23989453 DOI: 10.1177/1087057113501081 |
0.581 |
|
| 2014 |
Koss C, Nance S, Connelly M, Ma J, Shelat A, Cotton A, An Q, Cheng C, Metzger ML, Jeha S, Rubnitz JE, Downing JR, Guy RK, Gruber TA. Targeted Inhibition of the MLL Transcriptional Complex By Proteosome Inhibitors Elicits a High Response Rate in Relapsed/Refractory MLL Rearranged Leukemia Blood. 124: 972-972. DOI: 10.1182/Blood.V124.21.972.972 |
0.599 |
|
| 2014 |
Min J, Attia RN, Arnold LA, Teske K, Connelly M, Lemieux G, Ashrafi K, Shelat A, Guy RK. Abstract 5389: Discovery of small molecule inhibitors of the interaction between PPARγ and SMRT Cancer Research. 74: 5389-5389. DOI: 10.1158/1538-7445.Am2014-5389 |
0.427 |
|
| 2014 |
Boulos N, Dapper J, Patel Y, DeCuypere M, Bianski B, Mohankumar K, Jacus M, III BF, Wright K, Gajjar A, Shelat A, Stewart C, Guy R, Gilbertson R. 193 The identification of new therapies for ependymoma subgroups European Journal of Cancer. 50: 63. DOI: 10.1016/S0959-8049(14)70319-3 |
0.333 |
|
| 2013 |
Chen X, Stewart E, Shelat AA, Qu C, Bahrami A, Hatley M, Wu G, Bradley C, McEvoy J, Pappo A, Spunt S, Valentine MB, Valentine V, Krafcik F, Lang WH, et al. Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell. 24: 710-24. PMID 24332040 DOI: 10.1016/J.Ccr.2013.11.002 |
0.337 |
|
| 2013 |
Jane Tseng Y, Martin E, G Bologa C, Shelat AA. Cheminformatics aspects of high throughput screening: from robots to models: symposium summary. Journal of Computer-Aided Molecular Design. 27: 443-53. PMID 23636795 DOI: 10.1007/S10822-013-9646-6 |
0.378 |
|
| 2013 |
Vrijens K, Lin W, Cui J, Farmer D, Low J, Pronier E, Zeng FY, Shelat AA, Guy K, Taylor MR, Chen T, Roussel MF. Identification of small molecule activators of BMP signaling. Plos One. 8: e59045. PMID 23527084 DOI: 10.1371/Journal.Pone.0059045 |
0.365 |
|
| 2012 |
Guiguemde WA, Shelat AA, Garcia-Bustos JF, Diagana TT, Gamo FJ, Guy RK. Global phenotypic screening for antimalarials. Chemistry & Biology. 19: 116-29. PMID 22284359 DOI: 10.1016/J.Chembiol.2012.01.004 |
0.616 |
|
| 2012 |
Iconaru LI, Shelat A, Zuo J, Kriwacki RW. A Quest for Small Molecule Inhibitors of the Cell Cycle Regulator, P27 Biophysical Journal. 102: 635a. DOI: 10.1016/J.Bpj.2011.11.3455 |
0.389 |
|
| 2011 |
Atkinson JM, Shelat AA, Carcaboso AM, Kranenburg TA, Arnold LA, Boulos N, Wright K, Johnson RA, Poppleton H, Mohankumar KM, Féau C, Phoenix T, Gibson P, Zhu L, Tong Y, et al. An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell. 20: 384-99. PMID 21907928 DOI: 10.1016/J.Ccr.2011.08.013 |
0.617 |
|
| 2011 |
Cui J, Chai SC, Shelat AA, Guy RK, Chen T. An automated approach to efficiently reformat a large collection of compounds. Current Chemical Genomics. 5: 42-7. PMID 21804905 DOI: 10.2174/1875397301105010042 |
0.594 |
|
| 2011 |
Bouck DC, Shu P, Cui J, Shelat A, Chen T. A High-content screen identifies inhibitors of nuclear export of forkhead transcription factors Journal of Biomolecular Screening. 16: 394-404. PMID 21471460 DOI: 10.1177/1087057110397889 |
0.425 |
|
| 2011 |
Atkinson JM, Shelat AA, Kranenburg TA, Carcaboso AM, Arnold A, Wright KD, Johnson RA, Poppleton H, Mohankumar KM, Gibson P, Phoenix TN, Zhu L, Tong Y, Eden C, Gajjar A, et al. Abstract 4759: Integrated in vitro and in vivo screening of tumor and normal neural stem cells identifies potential new treatments of ependymoma Cancer Research. 71: 4759-4759. DOI: 10.1158/1538-7445.Am2011-4759 |
0.639 |
|
| 2011 |
Vrijens K, Lin W, Cui J, Shelat A, Taylor M, Guy KR, Chen T, Roussel MF. Abstract 4522: Identification of small molecule agonists/activators of BMP-2, 4, 7 signaling Cancer Research. 71: 4522-4522. DOI: 10.1158/1538-7445.Am2011-4522 |
0.412 |
|
| 2010 |
Guiguemde WA, Shelat AA, Bouck D, Duffy S, Crowther GJ, Davis PH, Smithson DC, Connelly M, Clark J, Zhu F, Jiménez-DÃaz MB, Martinez MS, Wilson EB, Tripathi AK, Gut J, et al. Chemical genetics of Plasmodium falciparum. Nature. 465: 311-5. PMID 20485428 DOI: 10.1038/Nature09099 |
0.796 |
|
| 2010 |
Tu Y, Jeffries C, Ruan H, Nelson C, Smithson D, Shelat AA, Brown KM, Li XC, Hester JP, Smillie T, Khan IA, Walker L, Guy K, Yan B. Automated high-throughput system to fractionate plant natural products for drug discovery. Journal of Natural Products. 73: 751-4. PMID 20232897 DOI: 10.1021/Np9007359 |
0.762 |
|
| 2010 |
Smithson DC, Lee J, Shelat AA, Phillips MA, Guy RK. Discovery of potent and selective inhibitors of Trypanosoma brucei ornithine decarboxylase. The Journal of Biological Chemistry. 285: 16771-81. PMID 20220141 DOI: 10.1074/Jbc.M109.081588 |
0.802 |
|
| 2010 |
Smithson DC, Shelat AA, Baldwin J, Phillips MA, Guy RK. Optimization of a non-radioactive high-throughput assay for decarboxylase enzymes. Assay and Drug Development Technologies. 8: 175-85. PMID 20085486 DOI: 10.1089/Adt.2009.0249 |
0.787 |
|
| 2010 |
Reed D, Shen Y, Shelat AA, Arnold LA, Ferreira AM, Zhu F, Mills N, Smithson DC, Regni CA, Bashford D, Cicero SA, Schulman BA, Jochemsen AG, Guy RK, Dyer MA. Identification and characterization of the first small molecule inhibitor of MDMX. The Journal of Biological Chemistry. 285: 10786-96. PMID 20080970 DOI: 10.1074/Jbc.M109.056747 |
0.758 |
|
| 2009 |
Mallari JP, Shelat AA, Kosinski A, Caffrey CR, Connelly M, Zhu F, McKerrow JH, Guy RK. Structure-guided development of selective TbcatB inhibitors. Journal of Medicinal Chemistry. 52: 6489-93. PMID 19769357 DOI: 10.1021/Jm900908P |
0.797 |
|
| 2009 |
Shelat AA, Guy RK. A road less traveled by: exploring a decade of Ellman chemistry. Bioorganic & Medicinal Chemistry. 17: 1088-93. PMID 18343129 DOI: 10.1016/J.Bmc.2008.02.087 |
0.561 |
|
| 2009 |
Atkinson JM, Shelat A, Johnson R, Wright K, Poppleton H, Mohankumar KM, Feau C, Arnold A, White E, Kranenburg T, Guy RK, Gilbertson RJ. Abstract A52: An interspecies genomics based high‐throughput screen for novel treatments of ependymoma Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-A52 |
0.645 |
|
| 2008 |
Mallari JP, Shelat A, Kosinski A, Caffrey CR, Connelly M, Zhu F, McKerrow JH, Guy RK. Discovery of trypanocidal thiosemicarbazone inhibitors of rhodesain and TbcatB. Bioorganic & Medicinal Chemistry Letters. 18: 2883-5. PMID 18420405 DOI: 10.1016/J.Bmcl.2008.03.083 |
0.779 |
|
| 2008 |
Mallari JP, Shelat AA, Obrien T, Caffrey CR, Kosinski A, Connelly M, Harbut M, Greenbaum D, McKerrow JH, Guy RK. Development of potent purine-derived nitrile inhibitors of the trypanosomal protease TbcatB. Journal of Medicinal Chemistry. 51: 545-52. PMID 18173229 DOI: 10.1021/Jm070760L |
0.779 |
|
| 2007 |
Mills NL, Shelat AA, Guy RK. Assay Optimization and Screening of RNA-Protein Interactions by AlphaScreen. Journal of Biomolecular Screening. 12: 946-55. PMID 17942787 DOI: 10.1177/1087057107306128 |
0.598 |
|
| 2007 |
Shelat AA, Guy RK. Scaffold composition and biological relevance of screening libraries. Nature Chemical Biology. 3: 442-6. PMID 17637770 DOI: 10.1038/Nchembio0807-442 |
0.578 |
|
| 2007 |
Shelat AA, Guy RK. The interdependence between screening methods and screening libraries. Current Opinion in Chemical Biology. 11: 244-51. PMID 17524728 DOI: 10.1016/J.Cbpa.2007.05.003 |
0.593 |
|
| 2007 |
Fujii N, Shelat A, Hall RA, Guy RK. Design of a selective chemical probe for class I PDZ domains. Bioorganic & Medicinal Chemistry Letters. 17: 546-8. PMID 17074480 DOI: 10.1016/J.Bmcl.2006.10.027 |
0.498 |
|
| 2006 |
Weisman JL, Liou AP, Shelat AA, Cohen FE, Guy RK, DeRisi JL. Searching for new antimalarial therapeutics amongst known drugs. Chemical Biology & Drug Design. 67: 409-16. PMID 16882315 DOI: 10.1111/j.1747-0285.2006.00391.x |
0.585 |
|
| 2006 |
Arnold LA, Estébanez-Perpiñá E, Togashi M, Shelat A, Ocasio CA, McReynolds AC, Nguyen P, Baxter JD, Fletterick RJ, Webb P, Guy RK. A high-throughput screening method to identify small molecule inhibitors of thyroid hormone receptor coactivator binding. Science's Stke : Signal Transduction Knowledge Environment. 2006: pl3. PMID 16804159 DOI: 10.1126/Stke.3412006Pl3 |
0.552 |
|
| 2006 |
MacKey ZB, Baca AM, Mallari JP, Apsel B, Shelat A, Hansell EJ, Chiang PK, Wolff B, Guy KR, Williams J, McKerrow JH. Discovery of trypanocidal compounds by whole cell HTS of Trypanosoma brucei Chemical Biology and Drug Design. 67: 355-363. PMID 16784460 DOI: 10.1111/J.1747-0285.2006.00389.X |
0.771 |
|
| 2005 |
Feng BY, Shelat A, Doman TN, Guy RK, Shoichet BK. High-throughput assays for promiscuous inhibitors. Nature Chemical Biology. 1: 146-8. PMID 16408018 DOI: 10.1038/Nchembio718 |
0.681 |
|
| 2005 |
Arnold LA, Estébanez-Perpiñá E, Togashi M, Jouravel N, Shelat A, McReynolds AC, Mar E, Nguyen P, Baxter JD, Fletterick RJ, Webb P, Guy RK. Discovery of small molecule inhibitors of the interaction of the thyroid hormone receptor with transcriptional coregulators. The Journal of Biological Chemistry. 280: 43048-55. PMID 16263725 DOI: 10.1074/Jbc.M506693200 |
0.491 |
|
| 2005 |
Anderson MO, Shelat AA, Guy RK. A solid-phase approach to the phallotoxins: total synthesis of [Ala7]-phalloidin. The Journal of Organic Chemistry. 70: 4578-84. PMID 15932292 DOI: 10.1021/jo0503153 |
0.618 |
|
| 2003 |
Springsteel MF, Galietta LJ, Ma T, By K, Berger GO, Yang H, Dicus CW, Choung W, Quan C, Shelat AA, Guy RK, Verkman AS, Kurth MJ, Nantz MH. Benzoflavone activators of the cystic fibrosis transmembrane conductance regulator: towards a pharmacophore model for the nucleotide-binding domain. Bioorganic & Medicinal Chemistry. 11: 4113-20. PMID 12927873 DOI: 10.1016/S0968-0896(03)00435-8 |
0.498 |
|
| 2003 |
Yang H, Shelat AA, Guy RK, Gopinath VS, Ma T, Du K, Lukacs GL, Taddei A, Folli C, Pedemonte N, Galietta LJ, Verkman AS. Nanomolar affinity small molecule correctors of defective Delta F508-CFTR chloride channel gating. The Journal of Biological Chemistry. 278: 35079-85. PMID 12832418 DOI: 10.1074/jbc.M303098200 |
0.439 |
|
| Show low-probability matches. |